Introduction
The identification of tumour markers would greatly facilitate the detection and treatment of cancer. Carcinoembryonic antigen (CEA) (Gold & Freedman 1965) appears to be associated with colorectal cancer. However, it seems to be of limited value in the detection of early tumours (Laurence et al. 1972) and currently this marker is being evaluated in the demonstration of recurrent malignant disease following surgery. Thus a rise of plasma CEA after colonic resection may infer progression of the tumour before this can be detected clinically and may indicate the need for a second-look operation or additional therapy (Minton et al. 1978 , Nicholson & Aust 1978 . Similarly, a rise of CEA in patients already receiving chemotherapy on an adjuvant, long-term basis may suggest that this treatment is no longer effective. In these circumstances, it may be appropriate to withhold further treatment or to try alternative drugs.
We have measured serial plasma CEA levels in a number of patients left with residual tumour following palliative resection of colorectal cancer. Some of those patients received repeated courses ofchemotherapy and others supportive treatment alone. The study examines the changes in CEA levels and relates them to the clinical status of the patient and coincident therapy.
Methods
The patients reported in this study were amongst those participating in a randomized trial of chemotherapy following palliative resection of colorectal cancer. All patients had a resection of colorectal cancer leaving behind macroscopic quantities of tumour, though of a small total residual bulk. The residual sites of tumour were recorded as: (0) local -where there was local extension of the tumour; (b) nodal-where there were clinically involved nodes remaining, with histological confirmation of involved nodes in the resected specimen; (c) hepatic -where small hepatic metastases were noted, individually not greater than 2 em in diameter and in total representing less than 10% of the liver bulk; (d) peritoneal-where peritoneal tumour seedlings remained, with histological confirmation of at least one of the seedlings.
Exclusion criteria for entry into the main study included any previous chemotherapy or radiotherapy, severe malnutrition, and significant impairment of renal function.
Randomization of patients took place after operation into a treatment group and an observation group. The former received chemotherapy, within two months of surgery, in the form of S-day courses of intravenous S-ftuorouracil (300 mg/m-) every eight weeks, together with a single oral dose of methyl chlorethyl cyclohexyl nitrosourea (130 mg/m 2 ) added to alternate courses, for two years.where possible. Both groups of patients were followed up on an outpatient basis and were examined at monthly intervals for clinical evidence of progression of their residual tumour. Patients were then treated symptomatically or with alternative chemotherapy at the discretion of the clinician.
This study reports on 43 patients overthe first yearoffollow up. Because CEA measurements were initially only performed on patients receiving chemotherapy, there is an inequality in sample sizes with 27 patients in the treatment group and 16 in the observation group. Further details regarding the patients' age and sex and the site and differentiation of the primary tumours are shown in Table 1 . The distribution of the sites of residual disease for the two groups is shown in Figure 1 . A Venn diagram is used since an individual may have had more than one site of residual disease. For example, five patients in the treatment group had hepatic involvement and two of these patients had additional sites of residual disease; one with local extension and one with both local extension and nodal deposits. Two patients in the observation group had liver involvement and both had additional sites of tumour.
Blood samples for measurement of CEA levels were taken monthly and the plasma separated and stored until subsequent analysis by the Chester Beatty Research Institute, London. The CEA assay was performed by Professor Munro Neville's laboratory using the technique described by Laurence et 01. (1972) , with an upper limit of normal of 30 ng/ml, A total of 304 samples taken from the 43 patients during the year of follow up are available for analysis. Figure To facilitate the comparison of the analysis of CEA levels, logarithmic values are used. As a result, the upper limit of normal in this study (30 ng/ml) is 1.48.The initial CEA values were estimated 4-8 weeks following colonic resection when the disturbance from surgery had settled (Mach et al. 1974 ).
Results
Of the 43 patients studied after operation and prior to chemotherapy, the mean log CEA was 1.19 and only 3 patients exceeded 1.48, despite the fact that all patients were known to have residual tumour ( Figure 2) . Similarly, the mean log CEA at 3 months for the total group remained at 1.26 but 6 patients now had abnormal values. Thereafter the mean values of the total group exceeded the upper limit of normality ( Figure 2 ) and increasing numbers of patients showed elevated CEA values. About one half of the patients had levels of CEA well within the normal range during the first postoperative year despite the evidence of residual disease documented at operation. Figure 3 demonstrates the mean log CEA values for patients receiving chemotherapy and for those patients under observation. Though there is no statistical difference between the two groups of patients, there appears to be a more rapid rise of CEA values in the observation group followed by a decline. This results from a number of early deaths. To unmask this effect, the groups have been further divided into patients with clinical evidence of progression within 12 months of resection and those patients who appeared clinically stable. Within this first year 20 patients showed clinical evidence of progression, 6 from the observation group and 14 of those receiving chemotherapy. Figure 4 demonstrates the change in mean log CEA values for the patients who showed clinical evidence of progression within 12 months of operation, compared with those who did not. Both groups start with a mean CEA value within normal limits, but by 3 months there is some difference detectable between the two groups. Patients without progression have a mean CEA level which remains within the normal range over the 12 months but patients with progression demonstrate a steady rise in values above the normal limit. This difference in CEA level between the two groups is significant from 3 months onwards (P<O.OS, Wilcoxon Signed Rank Test). However, it should be noted that 3 patients with clinical progression had CEA levels within the normal range at 12 months.
Treatment group versus observation group

Patients withprogression versus those without progression
To assess the effect of chemotherapy on the evolution, of the CEA level, Figure 5 demonstrates the mean log CEA values in all the patients without clinical progression and compares the treatment group with the observation group. Though there is an apparent trend towards higher CEA levels at 9 and 12 months in the observation group, the values are never significantly different on a statistical basis, but follow up beyond 12 months may eventually demonstrate a valid difference. Figure 6 examines the mean log CEA levels in patients with clinical progression in the chemotherapy-treated group and in the observation group. Because of a shorter period of survival of these patients, the time scale of this histogram is altered. There is a distinct elevation of CEA by 3 months in the observation group with very marked elevations up to 8 months. In contrast, the mean CEA levels in the chemotherapy-treated group are lower and the values are clearly increasing at a slower rate. The difference oflog CEA levels is statistically significant at 4 months (P<O.Ol), but because of loss of patients from the groups the~e differences are no longer significant at 6 and 8 months.
Clinical outcome
The results of this clinical trial will require more prolonged follow up. However, during the first 12 months of study 14 of 27 patients treated with chemotherapy progressed and 7 died. This compares with 6 of 16 patients in the observation group who progressed and also died during this period.
Since the majority of initial CEA levels proved to be in the normal range, it is not possible to relate these initial values to the subsequent clinical course. Of 3 patients with a high initial value, 2 have progressed but the remaining patient, who was a heavy cigarette smoker with chronic bronchitis, remains without evidence of progression.
Rate ofriseofCEA
To assess the significance of serial monitoring of CEA levels in these patients, the rate of rise of CEA values in the individual has been examined. To allow comparison, these are divided into three patterns by virtue of the CEA value reached six months after resection and related to clinical outcome (Figure 7) . One patient died from her tumour within 6 months and is not included. The fast-rising pattern included patients who had reached a log CEA value of 2.00 or above at 6 months; the intermediate pattern a value between 1.48and 2.00; and in the slowrise group the value was still within normal limits. Of the 10 patients in the first group (S received chemotherapy), 9 had shown evidence of progression within 12 months and 7 had Figure 7 . Clinical progression and mortality of patients whose rates of rise of CEA might be considered rapid. intermediate or slow. One patient who died at 4 months from cancer with a normal CEA level does not appear in these results died. Twenty-five patients fell into the slow-rise pattern and within the year only 5 patients had shown evidence of progression. Seven patients had an intermediate rate of rise of CEA, with 5 showing evidence of progression within the year of follow up, 2 of whom died. Of interest, the patients in this group not only showed an improved length of survival compared with those showing a fast rise of CEA, but also were all receiving chemotherapy.
Once elevated, the trend for CEA values was to rise progressively; however there were 15 recorded falls in sequential samples, occurring in 9 patients. Eight of these patients were receiving chemotherapy from the start and the last was the one patient in the observation group who received chemotherapy following clinical evidence of progression.
Discussion
An elevation of plasma CEA is found in 30-70% of patients with colorectal cancer before operation and depends upon the pathological extent of the tumour. There is some suggestion that carcinomas arising from the right side of the colon and rectum are not associated with elevated CEA so commonly (Livingstone et al. 1974) .
In patients with normal postoperative CEA levels, a subsequent elevation may indicate recurrent malignancy provided that elevation is of significant magnitude (Ravry et al. 1974) . However, the lack of sensitivity of the test is shown by the fact that only 3 of our 43 patients with known residual disease following incomplete resection had elevated CEA levels 2 months after operation. Indeed, only one patient of the 7 with small liver metastases at operation had an elevated initial postoperative level. Furthermore, in 5 patients there was clinical evidence oftumour progression prior to any elevation of CEA level. Similar findings have been reported by Moertel et al. (1978) and would suggest that the use of serial monitoring of CEA levels to detect recurrent disease would only detect a tumour load too extensive to becured by secondlook surgery. However, CEA may be an adequate tumour marker with which to monitor the effects of irradiation, chemotherapy and immunotherapy. Both irradiation and chemotherapy in patients with advanced disease have been shown to be associated with a reduction in CEA levels and with objective evidence of tumour response, though the relationship is not absolute and discordant results are often noted (Herrera et al. 1977 , Ravry et al. 1974 .Indeed, a recent study of patients receiving chemotherapy for advanced colorectal cancer has shown that patient survival correlates more closely with objective tumour response than with measured CEA decrease (Shani et 01. 1978) .
. The most appropriate application for a marker such as CEA may be as an assessment of the effect of chemotherapy in patients who have a definite, but objectively unmeasurable, tumour load.
In this study it would seem that not only does the CEA level increase with the expected progression of the residual tumour but that this rise is slower in patients receiving chemotherapy, even in those patients with more rapidly-growing tumours recurring clinically within one year. In these patients with early progression it may seem that chemotherapy has affected CEA levels alone without any effect on the tumour growth; Herrera et al. (1977) have suggested that nitrosoureas may lower the CEA regardless of the patients' tumour response. However, in our group of patients showing a fast progression of tumour growth, there was a difference in mortality rate at one year between patients receiving chemotherapy and those under observation, and this suggests that there was some response to treatment.
It remains to be seen whether serial monitoring of CEA levels in the individual has any value in such circumstances. Certainly, there are no other recognized methods of monitoring tumour response at present and the results for the group as a whole suggest that we may be observing some real effect. It is of interest in the arbitrary analysis of the rates of rise of CEA, that the fast risers show a poorer prognosis irrespective of receiving chemotherapy or not. Such a fast rise obviously indicates rapid tumour growth and would point to the futility of chemotherapy and perhaps spare the patient unnecessary additional discomfort. Patients with a slower rise in postoperative CEA levels have a more prolonged survival which may reflect a less aggressive tumour (Staab et al. 1978) or control by host defences or chemotherapy. Thus the conversion of a rapid-rise CEA slope to a less steep curve by chemotherapy may be an indication of effective drug action paralleled by an incomplete but clinically useful antitumour effect. Ifthis proved a consistent finding, it would be of value to oncologists in the management of patients with colorectal cancer.
